What the FDA labels say about taking them together
Mycophenolic acid and pantoprazole
Mycophenolic acid's FDA label of July 29, 2026 names pantoprazole in its drug interactions section, and pantoprazole's label names mycophenolic acid too. The pantoprazole label: “Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.”
Check it at the source: the mycophenolic acid FDA label on DailyMed (effective July 29, 2026, Novartis Pharmaceuticals Corporation); the pantoprazole FDA label on DailyMed (effective May 18, 2026, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.).
What does the mycophenolic acid label say about pantoprazole?
Mycophenolic acid label, drug interactionsAdministration of pantoprazole at a dose of 40 mg twice daily for 4 days to healthy volunteers did not alter the pharmacokinetics of a single dose of Myfortic [see Clinical Pharmacology (12.3)].
Source: FDA drug label (Myfortic), Novartis Pharmaceuticals Corporation, effective July 29, 2026 (SPL set eed26501-890d-4ff6-88e7-6dbea4726e53), via openFDA; the full label on DailyMed
What does the pantoprazole label say about mycophenolic acid?
Pantoprazole label, drug interactionsClinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. Intervention: Mycophenolate mofetil (MMF): Co-administration of pantoprazole sodium in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH …
Pantoprazole Sodium label (Hikma Pharmaceuticals USA Inc., July 19, 2023), drug interactionsDrugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, n ilotinib, mycophenoloate mofetil, ketoconazole/itraconazole) C linical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity I ntervention: Mycophenolate mofetil (MMF): Co-administration of pantoprazole sodium in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH [see)]. …
Source: FDA drug label (Pantoprazole Sodium, NDA209463), Hikma Pharmaceuticals USA Inc., effective July 19, 2023 (SPL set 1e102c44-232b-4aaf-b457-2a740c47193a), via openFDA
Source: FDA drug label (Protonix Delayed-Release), Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective May 18, 2026 (SPL set 08098cb2-c048-4640-f387-6beec4a38936), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Mycophenolic acid | Pantoprazole | |
|---|---|---|
| Labeled for | Organ transplant rejection | Acid reflux and ulcers |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0996 per tablet 180 mg tablet | $0.0358 per tablet 40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once